What is the 13F Pro Quality Score for XFOR?

13F Pro ranks X4 Pharmaceuticals, Inc (XFOR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XFOR's current score at https://13fpro.ai/research/XFOR (free sign-up required for the full ranking).

Which hedge funds own the most XFOR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of XFOR include MORGAN STANLEY, Empery Asset Management,, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/XFOR as soon as new 13F filings post.

Where does 13F Pro source XFOR data?

All X4 Pharmaceuticals, Inc fundamentals and ownership data come directly from SEC EDGAR. X4 Pharmaceuticals, Inc files with the SEC under CIK 1501697. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XFOR in?

X4 Pharmaceuticals, Inc (XFOR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XFOR research updated on 13F Pro?

XFOR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

X4 Pharmaceuticals, Inc(XFOR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1501697 XFOR stock profile & AI dashboard →

13F Pro Quality Score

29.3/100

Rank #2,415 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.1/100

Profitability

5.3/100

Balance Sheet

8.9/100

Earnings Quality

30.0/100

Free Cash Flow

4.7/100

Institutional Flow

67.3/100

Revenue Scale

8.5/100

Dilution Risk

4.1/100

XFOR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for X4 Pharmaceuticals, Inc (XFOR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XFOR at 29.3/100 on a 32-signal composite quality model, placing it at rank #2,415 of 2,879 stocks — the bottom half of the AI-ranked universe. XFOR scores in the top quartile across revenue growth (99.1). Areas of concern include free cash flow (4.7) and profitability (5.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), X4 Pharmaceuticals, Inc reports quarterly revenue of $2.5M, net income of $-20.2M, free cash flow of $-19.6M. Top institutional holders of XFOR by reported 13-F value include MORGAN STANLEY, Empery Asset Management,, FMR, based on the most recent SEC filings. XFOR trades on the Nasdaq exchange and files with the SEC under CIK 1501697. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XFOR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for X4 Pharmaceuticals, Inc directly from SEC EDGAR. X4 Pharmaceuticals, Inc's 13F Pro composite quality score has ranged between 11 and 46 since 2021, currently 29.3 — an improving long-term trajectory across 18 quarterly and live scoring snapshots.

✦

Fun facts about X4 Pharmaceuticals, Inc

Quirks, history, and lore behind XFOR — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Boston, Massachusetts · focused on rare diseases.
2
The Numbers
A small-cap biotech with no approved product revenue yet — it runs on grants, collaborations, and capital raises while burning cash on R&D, as clinical-stage biotechs do.
3
The History
Founded in the 2010s, the company was built around a single biological insight: that blocking a specific chemokine receptor could unlock treatments for conditions with almost no good options.
4
The Secret
Its entire pipeline targets the CXCR4 pathway — a molecular signaling route involved in immune cell trafficking that has been implicated in rare blood disorders and certain cancers.
5
The Lore
Its lead program targets WHIM syndrome — a rare immunodeficiency so uncommon it affects only a few hundred people worldwide — making it a textbook orphan disease play.
6
The Giveaway
The company's name literally contains a nod to its obsession: the "X4" in its identity refers directly to CXCR4, the receptor it has staked its entire scientific existence on.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$2.5M

Net Income

Q1 2026

$-20.2M

Free Cash Flow

Q1 2026

$-19.6M

D/E Ratio

Q1 2026

0.45

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+150.0% YoY

$6.5MFY 2025

FY22 $0.00FY23 $0.00FY24 $2.6MFY25 $6.5M

Net Income

-111.5% YoY

$-79.2MFY 2025

FY22 $-93.9MFY23 $-101.2MFY24 $-37.5MFY25 $-79.2M

Operating Income

-138.7% YoY

$-86.9MFY 2025

FY22 $-87.6MFY23 $-107.5MFY24 $-36.4MFY25 $-86.9M

EPS (Diluted)

+66.5% YoY

$-1.87FY 2025

FY22 $-1.52FY23 $-17.07FY24 $-5.59FY25 $-1.87

Total Assets

+98.3% YoY

$290.5MFY 2025

FY22 $155.6MFY23 $147.3MFY24 $146.4MFY25 $290.5M

Total Debt

+0.0% YoY

$75.0MFY 2025

FY22 $33.8MFY23 $55.0MFY24 $75.0MFY25 $75.0M

Op. Cash Flow

+34.6% YoY

$-85.6MFY 2025

FY22 $-77.1MFY23 $-96.5MFY24 $-130.9MFY25 $-85.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$6.5M +150.0%	$2.6M	$0.00	$0.00	$0.00	$0.00
Net Income	$-79.2M -111.5%	$-37.5M +63.0%	$-101.2M -7.8%	$-93.9M -5.8%	$-88.7M -68.0%	$-52.8M
Operating Income	$-86.9M -138.7%	$-36.4M +66.1%	$-107.5M -22.8%	$-87.6M -2.9%	$-85.1M -64.6%	$-51.7M
EPS (Diluted)	$-1.87 +66.5%	$-5.59 +67.3%	$-17.07 -1023.0%	$-1.52 +61.9%	$-3.99	—
Total Assets	$290.5M +98.3%	$146.4M -0.6%	$147.3M -5.4%	$155.6M +32.8%	$117.2M -27.1%	$160.7M
Total Debt	$75.0M +0.0%	$75.0M +36.4%	$55.0M +62.6%	$33.8M -0.4%	$33.9M +69.7%	$20.0M
Operating Cash Flow	$-85.6M +34.6%	$-130.9M -35.6%	$-96.5M -25.2%	$-77.1M -8.7%	$-70.9M -47.5%	$-48.1M

AI Insight: XFOR Financial Trends

X4 Pharmaceuticals maintains minimal revenue at $2M while burning through cash, though equity position strengthened significantly in recent quarters.

• Revenue remained flat at $2M from Q3 2025 through Q1 2026 after starting at $1M in Q3 2024.

• Operating cash flow improved from $-30M in Q2 2025 to $-20M in Q1 2026.

• Equity surged from $4M in Q2 2025 to $168M in Q1 2026, indicating significant capital raise.

⚠ Total debt remains unchanged at $75M across all periods while cash burn continues.

⚠ Net losses persist with $-20M in Q1 2026 despite improved cash flow trends.

AI Insight: XFOR Ratio Trends

X4 Pharmaceuticals shows modest improvement in profitability metrics but remains deeply unprofitable with ROE at -48.1% in Q1 2026.

• ROE improved from -193.5% in Q3 2025 to -48.1% in Q1 2026, showing gradual recovery from trough.

• ROA strengthened from -72.9% in Q3 2025 to -30.0% in Q1 2026, indicating better asset utilization.

• D/E ratio dramatically decreased from 18.89 in Q2 2025 to 0.45 in Q1 2026, reducing leverage significantly.

⚠ All profitability metrics remain deeply negative despite recent improvements, indicating ongoing fundamental challenges.

⚠ ROIC at -33.4% in Q1 2026 shows company still destroying shareholder value despite deleveraging efforts.

Get alerted when XFOR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for X4 Pharmaceuticals, Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XFOR

MORGAN STANLEY
$39.1M9,466,992 sh
Empery Asset Management, LP
$36.9M8,944,118 sh
FMR LLC
$33.5M8,103,400 sh
Bain Capital Life Sciences Investors, LLC
$32.9M7,967,454 sh
PERCEPTIVE ADVISORS LLC
$27.8M6,737,648 sh
Saturn V Capital Management LP
$26.7M6,456,646 sh
Deep Track Capital, LP
$26.2M6,339,535 sh
Kalehua Capital Management LLC
$15.4M3,722,840 sh
VANGUARD CAPITAL MANAGEMENT LLC
$14.4M3,497,612 sh
BRAIDWELL LP
$13.5M3,272,954 sh

Fund	Value	Shares
MORGAN STANLEY	$39.1M	9,466,992
Empery Asset Management, LP	$36.9M	8,944,118
FMR LLC	$33.5M	8,103,400
Bain Capital Life Sciences Investors, LLC	$32.9M	7,967,454
PERCEPTIVE ADVISORS LLC	$27.8M	6,737,648
Saturn V Capital Management LP	$26.7M	6,456,646
Deep Track Capital, LP	$26.2M	6,339,535
Kalehua Capital Management LLC	$15.4M	3,722,840
VANGUARD CAPITAL MANAGEMENT LLC	$14.4M	3,497,612
BRAIDWELL LP	$13.5M	3,272,954

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XFOR on your watchlist

Track score changes the day X4 Pharmaceuticals, Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XFOR a good stock to buy?

13F Pro's AI-powered analysis of X4 Pharmaceuticals, Inc (XFOR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XFOR are available on the XFOR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own XFOR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XFOR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of X4 Pharmaceuticals, Inc's investment landscape.